Bee Venom Peptide Melittin Dramatically Reduces Colitis Symptoms and Colon Damage in Mice

Melittin — a peptide from bee venom — dramatically improved clinical symptoms of ulcerative colitis in a DSS-induced mouse model, both as a standalone treatment and in combination with sulfasalazine (a standard UC drug). The peptide nearly eliminated histological damage in colon tissue and significantly reduced inflammation. Melittin also showed antioxidant effects by restoring the oxidant/antioxidant balance in damaged tissue. When used alongside sulfasalazine, melittin enhanced the conventional drug's therapeutic effect while attenuating its adverse effects.

C57BL/6 male mice were given dextran sulfate sodium (DSS) in drinking water to induce ulcerative colitis. Mice were then treated with melittin peptide alone, sulfasalazine alone, or the combination. Clinical symptoms (weight loss, stool consistency, bleeding) were monitored. Colon tissue was examined histologically for damage and inflammation. Oxidant/antioxidant balance was assessed in colon tissue.

Ulcerative colitis affects millions of people, and current treatments often have inadequate efficacy or significant side effects. This study suggests melittin could serve dual roles: as a standalone anti-inflammatory agent and as a combination partner that boosts the effectiveness of existing drugs while reducing their toxicity. The antioxidant mechanism adds another dimension beyond simple inflammation suppression.

Venom-derived peptides are an increasingly studied source of therapeutic molecules. Melittin is one of the most potent, but its clinical use has been limited by toxicity concerns (it can destroy red blood cells at high doses). This study adds to a growing body of evidence that at appropriate doses, melittin's anti-inflammatory properties could be harnessed for chronic inflammatory conditions like IBD. The combination approach — pairing melittin with conventional drugs to boost efficacy and reduce side effects — is particularly promising and mirrors strategies being explored with other antimicrobial peptides.

Mouse model of UC (DSS-induced) does not perfectly replicate human ulcerative colitis, which involves autoimmune components. Specific melittin doses were not detailed in the abstract. No toxicity profiling of melittin itself was reported — bee venom peptides can have significant side effects at higher doses. Sample sizes per group were not specified. Short-term study without long-term follow-up.